Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (3): 61-69.doi: 10.6040/j.issn.1671-7554.0.2024.0057

• Clinical Medicine • Previous Articles     Next Articles

Diagnostic value of dynamic changes of monocyte-to-lymphocyte ratio in acute-on-chronic hepatitis B liver failure

YANG Xueyan1,2, WU Yinping1,2, LYU Li3, ZHAO Zehua1,2, MA Hangyu1,2, LI Fengcai1,2, WANG Kai1,2, FAN Yuchen1,2   

  1. 1. Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    2. Institute of Hepatology, Shandong University, Jinan 250012, Shandong, China;
    3. Department of Outpatient and Follow Up Center, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2024-05-06

PDF (PC)

199

Abstract: Objective To explore the diagnostic value of dynamic changes of monocyte/lymphocyte ratio(MLR)in the prognosis of acute-on-chronic hepatitis B liver failure(ACHBLF). Methods The study involved ACHBLF patients from January 2010 to July 2023 in the Department of Hepatology, Qilu Hospital of Shandong University. Smooth curve fitting and threshold effect analysis were used to evaluate the nonlinear relationship between MLR and 30-day mortality of ACHBLF patients. Logistic regression analysis and the Boruta algorithm were used to assess risk factors for 30-day mortality. The receiver operating characteristic(ROC)curve was used to evaluate the diagnostic value of MLR and the bootstrap method was used for internal validation. Results In this study, 98 of the 243 individuals died within 30 days after hospitalization. MLR on the 8th day was identified as an independent risk factor for 30-day mortality of ACHBLF patients(OR=1.33, 95%CI:1.01-1.75, P=0.044), which was reported to be nonlinearly associated with 30-day mortality. Patients with MLR >1 on the 8th day showed a higher risk of mortality than those with MLR≤1(P<0.001). ROC curve showed that combination of MLR on the 8th day and the model for end-stage liver disease(MELD)score presented the area under the ROC of 0.775(95%CI: 0.69-0.86). Conclusion MLR>1 on the 8th day predicts poor 30-day prognosis in ACHBLF patients, and monitoring the dynamic changes of MLR is essential for the treatment of ACHBLF.

Key words: Acute-on-chronic hepatitis B liver failure, Monocyte /lymphocyte ratio, Prognosis, Risk factor

CLC Number: 

  • R575.3
[1] Beech C, Liu C, Zhang X. Pathology of acute and acute-on-chronic liver failure[J]. Clin Liver Dis, 2023, 27(3): 581-593.
[2] Ngu NLY, Flanagan E, Bell S, et al. Acute-on-chronic liver failure: controversies and consensus[J]. World J Gastroenterol, 2023, 29(2): 232-240.
[3] Sarin SK, Choudhury A, Sharma MK, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL): an update[J]. Hepatol Int, 2019, 13(4): 353-390.
[4] Br VK, Sarin SK. Acute-on-chronic liver failure: terminology, mechanisms and management[J]. Clin Mol Hepatol, 2023, 29(3): 670-689.
[5] Bhatti TK, Singal AK, Kwo PY. Viral hepatitis and acute-on-chronic liver failure[J]. Clin Liver Dis, 2023, 27(3): 617-630.
[6] Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver(APASL)2014[J]. Hepatol Int, 2014, 8(4): 453-471.
[7] Yao J, Liu T, Zhao Q, et al. Genetic landscape and immune mechanism of monocytes associated with the progression of acute-on-chronic liver failure[J]. Hepatol Int, 2023, 17(3): 676-688.
[8] Li J, Liang X, Jiang J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF[J]. Gut, 2022, 71(1): 163-175.
[9] Luo J, Li J, Li P, et al. Acute-on-chronic liver failure: far to go-a review[J]. Crit Care, 2023, 27(1): 259.
[10] Zawiah M, Hayat Khan A, Abu Farha R, et al. Neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio, and platelet-lymphocyte ratio in stroke-associated pneumonia: a systematic review and meta-analysis[J]. Curr Med Res Opin, 2023, 39(3): 475-482.
[11] Cheng HR, Song JY, Zhang YN, et al. High monocyte-to-lymphocyte ratio is associated with stroke-associated pneumonia[J]. Front Neurol, 2020, 11: 575809. doi: 10.3389/fneur.2020.575809.
[12] Hu G, Liu G, Ma JY, et al. Lymphocyte-to-monocyte ratio in esophageal squamous cell carcinoma prognosis[J]. Clin Chim Acta, 2018, 486: 44-48. doi: 10.1016/j.cca.2018.07.029.
[13] Hu RJ, Ma JY, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: prognostic significance and meta-analysis[J]. Clin Chim Acta, 2018, 481: 142-146. doi: 10.1016/j.cca.2018.03.008.
[14] Kang Y, Zhu X, Lin Z, et al. Compare the diagnostic and prognostic value of MLR, NLR and PLR in CRC patients[J]. Clin Lab, 2021, 67(9). doi: 10.7754/Clin.Lab.2021.201130.
[15] Hua Y, Sun JY, Lou YX, et al. Monocyte-to-lymphocyte ratio predicts mortality and cardiovascular mortality in the general population[J]. Int J Cardiol, 2023, 379: 118-126. doi: 10.1016/j.ijcard.2023.03.016.
[16] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599.
[17] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2022年版)[J].中华肝脏病杂志, 2022, 30(12): 1309-1331. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Zhonghua Gan Zang Bing Za Zhi, 2022, 30(12): 1309-1331.
[18] Moreau R, Gao B, Papp M, et al. Acute-on-chronic liver failure: a distinct clinical syndrome[J]. J Hepatol, 2021, 75(Suppl 1): S27-S35. doi: 10.1016/j.jhep.2020.11.047.
[19] World Medical Association.World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects[J]. JAMA, 2013, 310(20): 2191-2194.
[20] Ferstl P, Trebicka J. Acute decompensation and acute-on-chronic liver failure[J]. Clin Liver Dis, 2021, 25(2): 419-430.
[21] Zhang Y, Tan W, Wang X, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023, 79(5): 1159-1171.
[22] Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options[J]. Blood Purif, 2002, 20(3): 252-261.
[23] Jiang F, Lei J, Xiang J, et al. Monocyte-to-lymphocyte ratio: a potential novel predictor for acute kidney injury in the intensive care unit[J]. Ren Fail, 2022, 44(1): 1004-1011.
[24] Wang N, He S, Zheng Y, et al. The value of NLR versus MLR in the short-term prognostic assessment of HBV-related acute-on-chronic liver failure[J]. Int Immunopharmacol, 2023, 121: 110489. doi: 10.1016/j.intimp.2023.110489.
[25] Engelmann C, Zhang IW, Clària J. Mechanisms of immunity in acutely decompensated cirrhosis and acute-on-chronic liver failure[J]. Liver Int, 2023. doi: 10.1111/liv.15644.
[26] Cai J, Wang K, Han T, et al. Evaluation of prognostic values of inflammation-based makers in patients with HBV-related acute-on-chronic liver failure[J]. Medicine(Baltimore), 2018, 97(46): e13324. doi: 10.1097/MD.0000000000013324.
[27] Ruf A, Dirchwolf M, Freeman RB. From child-pugh to MELD score and beyond: taking a walk down memory lane[J]. Ann Hepatol, 2022, 27(1): 100535. doi: 10.1016/j.aohep.2021.100535.
[1] LIU Huijun, WU Zhaoting, WANG Yuli, XU Mingyang, LIU Xiao, KANG Yan, WANG Hongmei. Risk factors and early intervention for postpartum hemorrhage caused by lower uterine segment atony [J]. Journal of Shandong University (Health Sciences), 2026, 64(5): 61-66.
[2] HUANG Yuzhen, LYU Chen, YAN Lei, LI Shuaishuai, ZHANG Jingxue, LIU Chao, WANG Yinxia, SANG Yanyan, FANG Mei. Preventive effects of continued out-of-hospital management based on risk factor screening for ovarian hyperstimulation syndrome [J]. Journal of Shandong University (Health Sciences), 2026, 64(4): 92-99.
[3] PANG Jinhong, SU Ping, QIAO Junpeng, CHEN Qiaoqiao, CHEN Xueyu, ZHAO Yingying, SHI Jie, SUN Xiaoru, LI Qiuchun, HE Ruiyan, FAN Yiou, CHI Weiwei. Association between modifiable cardiovascular risk factors clustering patterns and stroke in the elderly population [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 11-19.
[4] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[5] ZHANG Zheng, WANG Jianwei, YANG Yujuan, ZHANG Yu, SONG Xicheng. Immunoglobulin E changes and risk factors in asthma children between 2008 and 2019 [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 32-36.
[6] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[7] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[8] JIA Ruoxi, LYU Li, LIU Hanyun, WU Yinping, LI Fengcai, ZHAO Zehua, WANG Kai, FAN Yuchen. Diagnostic value of blood cell count-related biomarkers in predicting 28-day mortality in acute-on-chronic hepatitis b liver failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 89-99.
[9] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
[10] LI Jing, HAO Panpan. Association between the heart rate variation and the prognosis in patients with acute heart failure at hospital admission and discharge [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 75-82.
[11] YANG Weifang, XU Hong, LIU Yuantao, ZHAO Huichen. Mechanism of thyroid-stimulating immunoglobulin in Graves disease recurrence and clinical significance [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 116-121.
[12] CHENG Zhenyu, LAI Qingguo, WU Mengtao. Advances in influencing factors of in-stent restenosis after iliofemoral vein stenting [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 112-117.
[13] LIU Wenzhao, ZHANG Yuan, MA Xiangping, WEI Fengtao, BU Peili. Correlation between the pre-endothelial activation and stress index and the mortality risk of patients with heart failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 27-35.
[14] CHEN Wenliang, WANG Huanhuan, HAO Jinjin, GONG Rui, ZHAO Qiang, ZHANG Fei, GAO Lei, DONG Jingxun. The role of lncRNA PVT1 in prognostic assessment and malignant progression of gastric cancer: a study based on nomogram model and functional cellular experiments [J]. Journal of Shandong University (Health Sciences), 2025, 63(10): 61-71.
[15] CHENG Yueqi, WANG Fei, YU Lixiang, ZHENG Chao, YU Zhigang. Progress in the study of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 17-24.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd